AstraZeneca said its newly approved SERD Etcamah failed to demonstrate benefit in a late-stage Phase III trial intended to support a label expansion into an earlier, untreated setting for advanced breast cancer. The company framed the result as a setback for the program’s planned positioning. The news lands soon after FDA clearance for Etcamah, highlighting the continued risk that even recently approved targeted agents can struggle to translate into different lines of therapy. For drug developers and partners, the update reinforces the importance of endpoint strategy when expanding across treatment-naïve populations and shifting disease settings.